With global share markets reeling from President Trump's new tariff threats and the prospect of trade wars, many ASX 200 stocks have taken a big hit this month.
The past few weeks have been challenging for investors, with most stocks falling sharply as trade tensions rise. But for those with a long-term focus and a little extra capital to invest, this could be a great opportunity to buy into quality companies that can weather the storm.
If you've got $2,000 to spare, there are still stocks worth considering that are built on solid fundamentals and have a positive growth outlook, regardless of tariffs.
Let's take a look at two that analysts rate as buys:
ResMed Inc. (ASX: RMD)
ResMed is a global leader in obstructive sleep apnoea (OSA) solutions and respiratory care.
Even with the potential disruption caused by Trump's trade tariffs, ResMed's outlook remains very strong thanks to ongoing robust patient growth in the CPAP therapy market. This growth is despite new competition from drugs targeting OSA, such as GLP-1 therapies, which have failed to dent the company's market share.
ResMed's success is rooted in its dominant position in the global market. It holds the number one spot in OSA treatment, and its products are a mainstay in healthcare worldwide. The company is also expanding its reach in new markets, particularly outside the US, positioning itself for future growth.
Goldman Sachs currently rates this ASX 200 stock as a conviction buy with a price target of $49.00. It believes the company's current trading multiple doesn't reflect its impressive growth prospects.
Overall, ResMed's consistent revenue generation and global market dominance provide investors with a reliable option in uncertain times.
Telstra Group Ltd (ASX: TLS)
Telstra is another ASX 200 stock that could shine despite the trade tariffs.
According to another note out of Goldman Sachs, the telco giant offers investors low-risk earnings and steady dividend growth.
Telstra's growth is underpinned by its strong position in the Australian mobile market, as well as its medium-term potential to unlock significant value by monetising its InfraCo Fixed assets. Goldman estimates that these assets could be worth anywhere between $22 billion to $33 billion, further boosting Telstra's financial position and growth potential.
Overall, in the face of global uncertainty, Telstra's stable cash flows and growing dividend yield make it an attractive option for investors looking to ride out market turbulence while benefiting from a company with a solid foundation and a positive medium term outlook.
Goldman Sachs has put a buy rating on Telstra's shares with a price target of $4.50.
The post Got $2,000? Buy these 2 ASX 200 stocks as Trump's Tariffs rock the markets appeared first on The Motley Fool Australia.
Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed and Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2025